Previous close | 3.8800 |
Open | 3.8000 |
Bid | 0.0000 x 1100 |
Ask | 0.0000 x 1100 |
Day's range | 3.5400 - 3.8000 |
52-week range | 2.0600 - 12.6100 |
Volume | |
Avg. volume | 98,693 |
Market cap | 302.791M |
Beta (5Y monthly) | 0.86 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appointed by the shareholders. Shareholders re-elected Douglas Williams, Monika Bütler, Alan Colowick, Tom Graney, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Sh
Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease Numerical differences favouring crenezumab over placebo were observed across the co-primary, multiple secondary and exploratory endpoints Initial data will be presented at the Alzheimer's Association International Conference (AAIC) on August 2, 2022 LAUSANNE, Switzerland, June 16, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: AC
LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis hotel in New York, NY from June 8-10, 2022. During the fireside chat, AC Immune’s CEO Andrea Pfeifer, will